Immunology and Biotherapies
16.6K views | +6 today
Follow
 
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert C FAURE's insight:

We choose Scoop.it as preferred curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Anti-virus monoclonal antibody could be elicited more efficiently with suitably optimized GP immunogens – Biotech Advisers

Anti-virus monoclonal antibody could be elicited more efficiently with suitably optimized GP immunogens – Biotech Advisers | Immunology and Biotherapies | Scoop.it
Anti-virus monoclonal antibody could be elicited more efficiently with suitably optimized GP immunogens - https://t.co/asRAdhmDnQ https://t.co/K757ARd6Eh

Via Krishan Maggon
more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Stem cells may significantly improve tendon healing by regulating inflammation: New research suggests the potential of tendon stem cells to improve healing and treatment for acute tendon injuries a...

Stem cells may significantly improve tendon healing by regulating inflammation: New research suggests the potential of tendon stem cells to improve healing and treatment for acute tendon injuries a... | Immunology and Biotherapies | Scoop.it
New research published online in The FASEB Journal suggests that tendon stem may be able to significantly improve tendon healing by regulating inflammation, which contributes to scar-like tendon healing and chronic matrix degradation. This has implications for the treatment of acute tendon injuries and chronic tendon disease.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The Immunotherapy Revolution – Science Life

Immunotherapy has revolutionized cancer treatment--but not for everyone. See how UChicago researchers are overcoming these barriers to help more patients.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Anticancer effects of the microbiome and its products : Nature Reviews Microbiology : Nature Research

more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Experimental therapy for immune diseases hits Achilles heel of activated T cells

Experimental therapy for immune diseases hits Achilles heel of activated T cells | Immunology and Biotherapies | Scoop.it
Immune diseases like multiple sclerosis and hemophagocytic lymphohistiocytosis unleash destructive waves of inflammation on the body, causing death or a lifetime of illness and physical impairment. With safe and effective treatments in short supply, scientists report in PNAS Early Edition discovery of an experimental treatment that targets an Achilles heel of activated immune cells -- killing them off and stopping autoimmune damage.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Ten years of biosimilars in Europe: development and evolution of the r | DDDT

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways Martin Schiestl,1 Markus Zabransky,2 Fritz Sörgel3,4 1Sandoz GmbH, Kundl, Austria; 2Sandoz Biopharmaceuticals, Hexal AG, Holzkirchen, Germany; 3Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; 4Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany Abstract: A biosimilar is defined by the European Medicines Agency as a biological medicine that is similar to another biological medicine that has already been authorized for use. A science-based regulatory framework to ensure high-quality biosimilars has been established in Europe since 2005 and is monitored and updated on an ongoing basis. The guiding principle of a biosimilar development program is to establish similarity between the biosimilar and the reference medicine by the best possible means, ensuring that the previously proven safety and efficacy of the reference medicinal product also applies to the biosimilar. Development of a biosimilar is underpinned by state-of-the-art analytical techniques to characterize both reference medicines and biosimilars. The extent and nature of the nonclinical in vivo studies and clinical studies to be performed depend on the level of evidence obtained in the previous step(s), including the robustness of the physicochemical, biological, and nonclinical in vitro data. Extrapolation is an important element of the biosimilarity concept. When biosimilar comparability has been demonstrated in one indication, extrapolation of the data package to other indications of the reference medicine could be acceptable, but needs to be scientifically justified and considered in light of the demonstrated level of sameness by all analytical, nonclinical, and clinical data. The credibility of the scientific basis behind the biosimilar concept, and quality of regulatory decision-making, is demonstrated by the successful approval and clinical use of 20 biosimilar medicines since 2006 when Omnitrope® was the first biosimilar to be approved. The regulatory environment for biosimilars continues to evolve, both in recognition of advances in technology/analytical methods and the availability of new targets for biosimilar development. Keywords: biosimilars, regulatory pathways, Omnitrope®
more...
No comment yet.
Suggested by LIGHTING
Scoop.it!

Targeting an integrin as a potential HIV therapeutic | Immunopaedia

α4β7 is a gut-homing integrin which is another receptor used by HIV to enter cells. For this reason, it plays a critical role in the pathogenesis of the virus.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials

Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials | Immunology and Biotherapies | Scoop.it
Objectives To investigate the safety of ofatumumab retreatment in rheumatoid arthritis. Methods Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and OFA110634) and a phase II extension trial (OFA111752) received individualised open-label ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart) ≥24 weeks following the first course and ≥16 weeks following further courses. Retreatment required evidence of clinical response followed by disease relapse. These studies were prematurely terminated by the sponsor to refocus development on subcutaneous delivery. Due to differences in study designs and populations, data are summarised separately for each study. Results 483 patients (243, 148 and 92 in OFA110635, OFA110634 and OFA111752 respectively) received up to 7 treatment courses of intravenous ofatumumab; cumulative duration of exposure was 463, 182 and 175 patient-years, respectively. Mean time between courses was 17–47 weeks. Ofatumumab induced a profound depletion of peripheral B-lymphocytes. Retreated patients derived benefit based on improvement in DAS28. Adverse events were reported for 93% (226/243), 91% (134/148) and 76% (70/92), serious adverse events for 18% (44/243), 20% (30/148) and 12% (11/92) and serious infections for 3% (8/243), 5% (7/148) and 1% (1/92) of patients in OFA110635, OFA110634 and OFA111752, respectively. The most common adverse events were infusion-related reactions during the first infusion of the first course (48–79%); serious infusion-related reactions were rare (<1% [1/243], 5% [8/148], and 1% [1/92] of patients). Two deaths occurred (fulminant hepatitis B virus infection and interstitial lung disease). Conclusions Ofatumumab was generally well tolerated with no evidence of increased safety risks with multiple retreatments. Serious infections were uncommon and did not increase over time. Trial Registration ClinicalTrials.gov 110635 ClinicalTrials.gov 110634 ClinicalTrials.gov 111752
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Transmembrane TNF-dependent uptake of anti-TNF antibodies

Transmembrane TNF-dependent uptake of anti-TNF antibodies | Immunology and Biotherapies | Scoop.it
(2017). Transmembrane TNF-dependent uptake of anti-TNF antibodies. mAbs: Vol. 9, No. 4, pp. 680-695. doi: 10.1080/19420862.2017.1304869

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Making antibodies minus the cells | Chemical & Engineering News

A cell-free synthesis method could speed up monoclonal antibody screening
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

The Revised (2013) Banff Classification for Antibody‐Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations

The Revised (2013) Banff Classification for Antibody‐Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations | Immunology and Biotherapies | Scoop.it
The Banff 2013 classification (Banff 2013) for antibody‐mediated rejection (ABMR) in renal allografts represents the first major revision of the original Banff classification for ABMR that wa
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells | Immunology and Biotherapies | Scoop.it
Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy.
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles : Nature Reviews Drug Discovery : Nature Research

more...
No comment yet.
Suggested by Société Francaise d'Immunologie
Scoop.it!

Comparison of Characteristics of Mesenchymal Stem Cells Obtained Mechanically and Enzymatically from Placenta and Umbilical Cord

Comparison of Characteristics of Mesenchymal Stem Cells Obtained Mechanically and Enzymatically from Placenta and Umbilical Cord | Immunology and Biotherapies | Scoop.it
Mesenchymal stem cells (MSC) are a good source for the cell therapy thanks to their abilities. MSCs exert very important immunomodulatory effects: they suppress T- and B-..
more...
No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
Scoop.it!

Stem cells show promise – but they also have a darker side

Stem cells show promise – but they also have a darker side | Immunology and Biotherapies | Scoop.it
Stem cells show potential for treating injuries, but some lab trials show they could be harmful too.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Unravelling the biology of SCLC: implications for therapy : Nature Reviews Clinical Oncology : Nature Research

more...
No comment yet.
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review
Scoop.it!

House Call: Types of Immunotherapy for Cancer

House Call: Types of Immunotherapy for Cancer | Immunology and Biotherapies | Scoop.it
Immunotherapy drugs include immune checkpoint inhibitors, cytokines, and modified T cells.

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Therapeutic targeting of the angiopoietin-TIE pathway : Nature Reviews Drug Discovery : Nature Research

more...
No comment yet.
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies 2014
Scoop.it!

Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development - Paucufs

Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development - Paucufs | Immunology and Biotherapies | Scoop.it
Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development by Cheng Liu and K. John Morrow Jr. About Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this …

Via Krishan Maggon
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease

Advances in the Use of Regulatory T-Cells for the Prevention and Therapy of Graft-vs.-Host Disease | Immunology and Biotherapies | Scoop.it
Regulatory T (Tregs) cells play a crucial role in immunoregulation and promotion of immunological tolerance. Adoptive transfer of these cells has therefore been of interest in the field of bone marrow and solid organ transplantation, autoimmune diseases and allergy medicine. In bone marrow transplantation, Tregs play a pivotal role in the prevention of graft-verus-host disease (GvHD). This has generated interest in using adoptive Treg cellular therapy in the prevention and treatment of GvHD. There have been several barriers to the feasibility of Treg cellular therapy in the setting of hematopoietic stem cell transplantation (HSCT) which include low Treg concentration in peripheral blood, requiring expansion of the Treg population; instability of the expanded product with loss of FoxP3 expression; and issues related to the purity of the expanded product. Despite these challenges, investigators have been able to successfully expand these cells both in vivo and in vitro and have demonstrated that they can be safely infused in humans for the prevention and treatment of GvHD with no increase in relapse risk or infections risk.
more...
No comment yet.
Rescooped by Gilbert C FAURE from CME-CPD
Scoop.it!

FREE CME ONLINE SYMPOSIUM - Oncology Central

FREE CME ONLINE SYMPOSIUM - Oncology Central | Immunology and Biotherapies | Scoop.it
On 21st – 22nd June, Oncology Central is hosting a free, CME-accredited, education symposium on the practical clinical aspects of immuno-oncology. Chaired by Professor Angus Dalgleish (St George’s, University of London), our online symposium is aimed at delivering oncology professionals key updates in this field, discussing how practices are changing and what continually emerging dataRead More

Via Krishan Maggon , Gilbert C FAURE
more...
No comment yet.
Rescooped by Gilbert C FAURE from Immunology
Scoop.it!

Treating Flu with Skin of Frog

Treating Flu with Skin of Frog | Immunology and Biotherapies | Scoop.it
Glands in frog skin secrete substances that possess broad antimicrobial function.
Holthausen et al. mined this soup of natural products and discovered a peptide that
destroys diverse human influenza strains (Holthausen et al., 2017). This study points
the way to the discovery of novel anti-influenza molecules targeting conserved elements
on influenza surface proteins.
more...
Gilbert C FAURE's curator insight, May 15, 11:20 AM
Witches knew it!
Rescooped by Gilbert C FAURE from Biotech Pharma Innovation in Immuno-Oncology & beyond. Cancer - Immunology - Immunotherapy.
Scoop.it!

5th Antibody Industrial Symposium 2017

Welcome to the 5th Antibody Industrial Symposium 2017 - AIS2017
Dear Colleagues,

We are proud to announce the 5th Antibody Industrial Symposium 2017 (AIS2017) that will be held the 27 and 28th of June 2017 in Tours, Loire Valley, France. This congress, jointly organized by the LabEx MAbImprove, Polepharma and MabDesign, is the continuation of the series of Industrial Symposia organized since 2013 (Antibody Biosimilars, MAbDosing, MAbDelivery, and Current and Next Generation Antibody Formats).

The Scientific committee has set-up an exciting program focusing on the following theme: “Antibody-Drug Conjugates: Design & Development for Therapy and Imaging in and beyond Cancer”, with keynote lectures, pitch talks of new creative projects, and industrial talks from leading pharmaceutical companies.

On the one hand, the AIS2017 is the ideal conference for scientists from various horizons, as Antibody-Drug Conjugates (ADCs) bring together people with many skills and various centers of interest, from many types of chemistry to biology through molecular modeling, bioconjugation and much more. On the other hand, the AIS2017 should interest academics as well as industrials, physicians and policy makers to exchange about therapeutic ADCs.

The successive approvals by the FDA of Adcetris® in 2011 and Kadcyla® in 2013 opened the way for many scientists hoping to reach Paul Ehrlich’s magic bullet vision. Indeed, an ADC results from the grafting of a powerful cytotoxic agent on a therapeutic antibody (MAb) through a judiciously constructed spacer arm (linker). It is a vectorized therapy which tackles the challenge to harness both strength of the selectivity of the MAb for its target and high potency of the payload against the malignancy. Therefore, it is not surprising that the topics covered in this symposium will be excitingly very wide: after an overview presentation of the area of research of ADCs, the search for new targets will be presented, opening the way either for new fields of applications of ADC in oncology and beyond, or for diagnostic purposes. Then, several approaches, ranking from new linkers to new payloads through new bioconjugation techniques, will enable the development of the next generation ADC. Such ADC will offer new challenges for their developability, scale-up and manufacturing, before going to the clinic, where their safety and efficacy will be assessed, to offer hopefully new opportunities for the treatment of patients who are non-responsive, resistant or relapsed.

To share the thrill about this new class of biodrugs, the program contains several opportunities for networking and for companies to showcase their new products and technologies, and dedicated time for business partnering.
The Symposium will take place at the Vinci International Convention Centre in the heart of Tours, providing easy transport link, and plenty of accommodation close to the venue.

Looking forward to welcoming you to the 5th Antibody Industrial Symposium 2017 in Tours.

Best regards,

The Scientific Committee, the LabEx MAbImprove, MabDesign and Polepharma


Via Dominique Blanchard
more...
No comment yet.
Scooped by Gilbert C FAURE
Scoop.it!

Current and emerging therapeutic targets for IBD : Nature Reviews Gastroenterology & Hepatology : Nature Research

Current and emerging therapeutic targets for IBD : Nature Reviews Gastroenterology & Hepatology : Nature Research | Immunology and Biotherapies | Scoop.it
Various therapeutic advances have led to a paradigm shift in the clinical management of patients with IBD. The introduction of immunosuppressive (such as azathioprine) and biologic agents (such as TNF blockers) has markedly reduced the need to use corticosteroids for therapy. Furthermore, the α4β7 integrin blocker vedolizumab has been introduced for clinical IBD therapy. Moreover, various new inhibitors of cytokines (for example, IL-6–IL-6R and IL-12–IL-23 blockers or apremilast), modulators of cytokine signalling events (for example, JAK inhibitors or SMAD7 blocker), inhibitors of transcription factors (for example, GATA3 or RORγt) and new anti-adhesion and anti-T-cell-activation and migration strategies (for example, β7 integrin, sphingosine 1-phosphate receptors and MAdCAM1 inhibitors, regulatory T-cell therapy and stem cells) are currently being evaluated in controlled clinical trials. This Review aims to provide a comprehensive overview about current and future therapeutic approaches for IBD therapy. Furthermore, potential mechanisms of action of these therapeutic approaches and their implications for clinical therapy in IBD are discussed.
Gilbert C FAURE's insight:
free for a limited time
more...
No comment yet.